RJFSA
CRMD icon

Raymond James Financial Services Advisors’s CorMedix CRMD Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$650K Sell
80,499
-2,446
-3% -$13.2K ﹤0.01% 2436
2024
Q2 		$359K Sell
82,945
-350
-0.4% -$1.78K ﹤0.01% 2764
2024
Q1 		$353K Buy
83,295
+1,461
+2% +$5.07K ﹤0.01% 2746
2023
Q4 		$308K Buy
81,834
+10,362
+14% +$35.7K ﹤0.01% 2724
2023
Q3 		$264K Sell
71,472
-780
-1% -$3.1K ﹤0.01% 2741
2023
Q2 		$286K Sell
72,252
-50
-0.1% -$247 ﹤0.01% 2687
2023
Q1 		$299K Sell
72,302
-505
-0.7% -$2.07K ﹤0.01% 2645
2022
Q4 		$307K Buy
72,807
+24,400
+50% +$86.3K ﹤0.01% 2569
2022
Q3 		$137K Buy
48,407
+6,037
+14% +$25.1K ﹤0.01% 2948
2022
Q2 		$170K Buy
42,370
+3,355
+9% +$12.5K ﹤0.01% 2899
2022
Q1 		$214K Sell
39,015
-3,015
-7% -$13.8K ﹤0.01% 2921
2021
Q4 		$191K Sell
42,030
-2,182
-5% -$10.8K ﹤0.01% 2987
2021
Q3 		$206K Buy
44,212
+695
+2% +$4.05K ﹤0.01% 2966
2021
Q2 		$299K Buy
43,517
+1,261
+3% +$10K ﹤0.01% 2721
2021
Q1 		$422K Buy
42,256
+16,986
+67% +$179K ﹤0.01% 2403
2020
Q4 		$188K Sell
25,270
-60
-0.2% -$408 ﹤0.01% 2735
2020
Q3 		$153K Buy
25,330
+580
+2% +$2.91K ﹤0.01% 2606
2020
Q2 		$156K Buy
24,750
+750
+3% +$3.47K ﹤0.01% 2548
2020
Q1 		$86K Buy
24,000
+3,815
+19% +$21.6K ﹤0.01% 2255
2019
Q4 		$147K Buy
20,185
+421
+2% +$2.57K ﹤0.01% 2645
2019
Q3 		$126K Buy
19,764
+1,464
+8% +$12.3K ﹤0.01% 2605
2019
Q2 		$164K Buy
18,300
+6,539
+56% +$51.3K ﹤0.01% 2587
2019
Q1 		$111K Buy
+11,761
New +$106K ﹤0.01% 2628
2017
Q2 		– Sell
-2,608
Closed -$21K – 2531
2017
Q1 		$21K Sell
2,608
-800
-23% -$7.64K ﹤0.01% 2367
2016
Q4 		$26K Sell
3,408
-90
-3% -$911 ﹤0.01% 2275
2016
Q3 		$44K Sell
3,498
-4,818
-58% -$45K ﹤0.01% 2212
2016
Q2 		$83K Buy
8,316
+1,190
+17% +$18.1K ﹤0.01% 2124
2016
Q1 		$94K Buy
+7,126
New +$69.2K ﹤0.01% 1907

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial Services Advisors's CRMD Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its CorMedix (CRMD) stake by 2.9% in Q3 2024, selling an estimated $13.2K and leaving 80,499 shares worth $650K. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

Raymond James Financial Services Advisors first reported a position in CRMD in Q1 2016 and has held it in 28 quarters since. 102 funds tracked by Wall St. Rank hold CRMD as of Q3 2024.

  • Raymond James Financial Services Advisors held 80,499 shares of CorMedix worth $650K as of Q3 2024.
  • Raymond James Financial Services Advisors sold 2,446 CorMedix shares in Q3 2024, an estimated $13.2K.
  • CorMedix made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2436 holding.
  • Raymond James Financial Services Advisors first reported a position in CorMedix in Q1 2016 and has held it in 28 quarters since.
  • 102 funds tracked by Wall St. Rank held CorMedix as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.